Loading stock data…
DBVT
$19.87-1.13 (-5.38%)
Market ClosedLast close May 1
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DBV Technologies S.A. in the Healthcare sector is trading at $19.87. The stock is currently 24% below its 52-week high of $26.18, remaining 22.8% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why DBVT maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.87
Potential Upside
5%
Whystock Fair Value$20.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$48.31+143.1%
Range$39.97 – $54.96
Fundamentals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.53%
Volume
Today's trading volume
153,641
Recent News
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
European equities traded in the US as American depositary receipts were trending marginally higher l
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending lower late Monday m
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Is It Too Late To Consider DBV Technologies (ENXTPA:DBV) After Its 1-Year 173% Surge?
Wondering if DBV Technologies at €3.62 is still priced for opportunity or if most of the upside is already in the rear-view mirror. The stock has recently posted returns of 3.4% over 7 days, 6.3% over 30 days, 11.0% year to date, 172.9% over 1 year, 19.4% over 3 years and a 64.1% decline over 5 years. Taken together, this gives a mixed picture of risk and potential reward. These moves sit against a backdrop of ongoing developments in its pharmaceutical and biotech activities. These factors...
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday